Improving or maintaining visual acuity is the main goal for the treatment of neovascular age-
related macular degeneration (nAMD). Current nAMD standard of care dictates frequent …

Eye is the unique sense organ with complex and sophisticated anatomy and physiology.
Being most instrumental for vision, it is secured by varied protective barriers; ranging from …

Purpose To evaluate efficacy and safety of intravitreal injections of aflibercept (IVT-AFL) treat-
and-extend (T&E) dosing regimens in treatment-naïve patients with exudative age-related …

Background A high-dose formulation of intravitreal aflibercept (8 mg) could improve
treatment outcomes in diabetic macular oedema (DMO) by requiring fewer injections than …

Purpose There is an urgent need to address how to best provide ophthalmic care for
patients with retinal disease receiving intravitreal injections with anti-vascular endothelial …

Retinal fluid as the major biomarker in exudative macular disease is accurately visualized by
high-resolution three-dimensional optical coherence tomography (OCT), which is used …

Methods: A randomized, open-label, Phase 3b/4 study that included treatment-naïve
patients aged≥ 50 years with the best-corrected visual acuity 73–25 Early Treatment …

Importance Advanced age-related macular degeneration (AMD) is a leading cause of
blindness in Western countries. Causal, modifiable risk factors need to be identified to …

Objectives This report aims to provide clear recommendations and practical guidance from a
panel of UK retinal experts on an aflibercept treat-and-extend (T&E) pathway that can be …

has multiple small lipid deposits called drusen (< 63 μm) and a smaller number of medium
drusen (63-125 μm) under the retina, or mild pigmentation abnormalities of the retinal …